137 Using a scenario approach to assess for the current and future demand of immunoglobulins Appendix A: Three-part scoping review search strategy and exclusion criteria (((”Pharmaceutical Preparations/economics”[Mesh] OR ”Pharmaceutical Preparations/supply and distribution”[Mesh] OR ”Immunologic Factors/economics”[Mesh] OR ”Immunologic Factors/supply and distribution”[Mesh] OR ”Immunoglobulins, Intravenous/economics”[majr] OR ”Legislation, Drug”[Mesh:NoExp]) AND (“plasma-derived”[tw] OR “plasma derived medical products”[tw] OR “plasma derived medicinal products”[tw] OR “plasma derived medicines”[tw] OR “plasma derived preparations”[tw] OR “plasma derived product”[tw] OR “plasma derived products”[tw] OR “plasma derived drug”[tw] OR “plasma derived components”[tw] OR “plasma derived concentrate”[tw] OR “plasma derived concentrates”[tw] OR “plasma derived biological medicines”[tw] OR “plasma derived blood products”[tw] OR “plasma derived protein”[tw] OR “plasma derived proteins”[tw] OR “plasma derived therapeutic products”[tw] OR “plasma derived therapeutic proteins”[tw] OR “plasma derived therapeutics”[tw] OR “plasma derived therapies”[tw] OR “plasma derived drugs” [tw] OR ((“PDMP”[tw] OR “PDMPs”[tw]) AND “plasma”[tw]) OR “Plasma Products”[tw] OR “Plasma Product”[tw] OR ((“Pharmaceutical Preparations”[mesh] OR “Biological Products”[mesh] OR “Biopharmaceutics”[mesh]) AND (“Plasma”[mesh] OR “plasma”[ti])) OR “Immunoglobulins, Intravenous”[Mesh] OR “Intravenous Immunoglobulin”[tw] OR “Intravenous Immunoglobulins”[tw] OR “Intravenous IG”[tw] OR “IVIG”[tw] OR “IVIGs”[tw] OR “Intravenous Immune Globulin”[tw] OR “IV Immunoglobulins”[tw] OR “Flebogamma DIF”[tw] OR “Gamunex”[tw] OR “Globulin-N”[tw] OR “Globulin N”[tw] OR “Intraglobin”[tw] OR “Intraglobin F”[tw] OR “Gammagard”[tw] OR “Gamimune”[tw] OR “Gamimmune”[tw] OR “Modified Immune Globulin”[tw] OR “Privigen”[tw] OR “Sandoglobulin”[tw] OR “Venoglobulin”[tw] OR “Venoglobulin-I”[tw] OR “Venoglobulin I”[tw] OR “Iveegam”[tw] OR “Alphaglobin”[tw] OR “Endobulin”[tw] OR “Gamimune N”[tw] OR “Gamimmune N”[tw] OR “Gammonativ”[tw])) OR ((“current practice”[tw] OR “current clinical practice”[tw] OR “practice”[ti] OR “usage”[ti] OR “daily practice”[tw] OR ”current usage”[tw] OR ”current use”[tw] OR ”common practice”[tw]) AND (“plasma-derived”[tw] OR “plasma derived medical products”[tw] OR “plasma derived medicinal products”[tw] OR “plasma derived medicines”[tw] OR “plasma derived preparations”[tw] OR “plasma derived product”[tw] OR “plasma derived products”[tw] OR “plasma derived drug”[tw] OR “plasma derived components”[tw] OR “plasma derived concentrate”[tw] OR “plasma derived concentrates”[tw] OR “plasma derived biological medicines”[tw] OR “plasma derived blood products”[tw] OR “plasma derived protein”[tw] OR “plasma derived proteins”[tw] OR “plasma derived therapeutic products”[tw] OR “plasma derived therapeutic proteins”[tw] OR “plasma derived therapeutics”[tw] OR “plasma derived therapies”[tw] OR “plasma derived drugs” [tw] OR ((“PDMP”[tw] OR “PDMPs”[tw]) AND “plasma”[tw]) OR “Plasma Products”[tw] OR “Plasma Product”[tw] OR ((“Pharmaceutical Preparations”[mesh] OR “Biological Products”[mesh] OR “Biopharmaceutics”[mesh]) AND (“Plasma”[mesh] OR “plasma”[ti])) OR “Immunoglobulins, Intravenous”[Mesh] OR “Intravenous Immunoglobulin”[tw] OR “Intravenous Immunoglobulins”[tw] OR “Intravenous IG”[tw] OR “IVIG”[tw] OR “IVIGs”[tw] OR “Intravenous Immune Globulin”[tw] OR “IV Immunoglobulins”[tw] OR “Flebogamma DIF”[tw] OR “Gamunex”[tw] OR “GlobulinN”[tw] OR “Globulin N”[tw] OR “Intraglobin”[tw] OR “Intraglobin F”[tw] OR “Gammagard”[tw] OR “Gamimune”[tw] OR “Gamimmune”[tw] OR “Modified Immune Globulin”[tw] OR “Privigen”[tw] OR “Sandoglobulin”[tw] OR “Venoglobulin”[tw] OR “Venoglobulin-I”[tw] OR “Venoglobulin I”[tw] OR “Iveegam”[tw] OR “Alphaglobin”[tw] OR “Endobulin”[tw] OR “Gamimune N”[tw] OR “Gamimmune N”[tw] OR “Gammonativ”[tw])) OR (((demand*[ti] NOT “on-demand”[ti]) OR “demands”[ti] OR “supply”[ti] OR “supplies”[ti] OR “supplied”[ti] OR “future demand”[tw] OR “future demands”[tw] OR “demand change”[tw] OR “demand changes”[tw] OR “demand characteristics”[tw] OR “demand prediction”[tw] OR “future supplies”[tw] OR “future supply”[tw] OR “supply and distribution”[subheading] OR “Resource Allocation”[mesh] OR ((“demand”[tw] OR “demands”[tw]) AND (“future”[tw] OR predict*[tw] OR “change”[tw] OR “changes”[tw] OR “changing”[tw]))) AND (“plasma-derived”[tw] OR “plasma derived medical products”[tw] OR “plasma derived medicinal products”[tw] OR “plasma derived medicines”[tw] OR “plasma derived preparations”[tw] OR “plasma derived product”[tw] OR “plasma derived products”[tw] OR “plasma derived drug”[tw] OR “plasma derived components”[tw] OR “plasma derived concentrate”[tw] OR “plasma derived concentrates”[tw] OR “plasma derived biological medicines”[tw] OR “plasma derived blood products”[tw] OR “plasma derived protein”[tw] OR “plasma derived proteins”[tw] OR “plasma derived therapeutic products”[tw]
RkJQdWJsaXNoZXIy MTk4NDMw